Strongbridge Biopharma (NASDAQ:SBBP) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Wednesday.
A number of other analysts have also commented on SBBP. Cantor Fitzgerald restated an “overweight” rating on shares of Strongbridge Biopharma in a research note on Wednesday, December 6th. Zacks Investment Research lowered shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, September 28th. ValuEngine lowered shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Strongbridge Biopharma in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Strongbridge Biopharma presently has a consensus rating of “Buy” and a consensus target price of $12.25.
Shares of Strongbridge Biopharma (NASDAQ SBBP) opened at $6.75 on Wednesday. The company has a market cap of $268.73 and a price-to-earnings ratio of -2.00. The company has a debt-to-equity ratio of -1.89, a quick ratio of 4.61 and a current ratio of 4.70. Strongbridge Biopharma has a one year low of $2.00 and a one year high of $8.85.
ILLEGAL ACTIVITY NOTICE: “Strongbridge Biopharma (SBBP) Lifted to “Buy” at BidaskClub” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://weekherald.com/2017/12/27/strongbridge-biopharma-sbbp-lifted-to-buy-at-bidaskclub.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.